Abstracts Archive

BackgroundAvailable methods for MRD detection in CTCL utilize primarily circulating cellular DNA, and sensitivity of MRD in cfDNA has been poorly characterized for CTCL.  Genomic heterogeneity of CTCL limits the utility of disease-specific MRD panels, and existing hybrid capture based cell-free...

Introduction:Peripheral T cell lymphoma (PTCL) continue to be, in general, associated with poor clinical outcome. In 2018, at time of disclosure of results of the T-cell Project 1 (TCP) study, we decided to launch the TCP 2.0, to have a contemporary understanding of the evolving landscape of T-cell ...

Background: CTCL patients face unique challenges due to visible and progressive symptoms. The aim of this study was to understand how patients navigate the psychosocial impact of visible disease manifestations and maintain their sense of identity and social relationships.Methods: We...

T-cell malignancies exhibit resistance to the standard therapy, CHOP, which results in limited anti-tumor activity and poor prognosis. This highlights a significant unmet medical need for novel treatment strategies. Given that CD5 is ubiquitously expressed on most T-cell malignancies, it represents ...

T-cell large granular lymphocyte leukemia (T-LGLL) is characterized by a clonal expansion of cytotoxic CD8+ T-cells. The pathogenesis of LGLL is not fully understood, and with no FDA-approved therapies, there is a need for a deeper understanding of the disease's molecular complexities and impact on ...

R/R PTCL patients require novel, lineage-specific therapies with manageable toxicity to bridge them to HSCT. A prior phase I/II study of duvelisib/romidepsin(D/R) reported ORR of 58% and CRR of 42% with reduced grade 3-4 transaminitis(14%) vs duv-monotherapy. We report real-world outcomes on a multi...

Aim: Large cell transformation of mycosis fungoides (LCTMF) is frequently associated with more aggressive clinical course and inferior survival than classical MF. Yet, LCTMF is not recognised in current staging systems. Herein, we describe characteristics, management and outcomes of p...

Background: Several B-cell malignancies  present evidence of stereotyped B-cell receptors and antigen driven pathogenesis. By contrast, this phenomenon has not been documented in T-cell lymphomas (TCL), an heterogeneous group of aggressive malignancies. Objective: This study aims to assess...

IntroductionImmunosequencing is an emerging clinical test to identify, quantify, and track dominant T-cell clones in cutaneous T-cell lymphoma (CTCL). Previous immunosequencing studies found tumor clone frequency (TCF), as defined by the percentage of the dominant malignant T-cell clone among other ...

Introduction: PTPN2 was identified as the essential gene for the growth and survival of ALK+ALCL based on the results of the whole genome loss of function screens in ALK+ALCL cells (SUDHL1, Karpas299, KIJK, SUPM2 and DEL). The first in class potent PTPN2/1 active site inhibitor ABBV CLS 484 (AC484) ...

Chemotherapy resistance in ENKTCL is poorly understood. We hypothesized that integrated omics would uncover molecular drivers of refractoriness to therapy in a topographically diverse series of cases with distinct treatment responses.We performed WGS(60x), WES(150-300x), and bulk RNA-seq on 52 ...

Natural Killer Large Granular Lymphocyte Leukemia (NK-LGLL) is a distinct LGLL subtype, accounting for 10-15% of LGLL cases. We present the first multimodal single-cell analysis of NK-LGLL in peripheral blood mononuclear cells from six patients and four healthy donors. We found that leukemic NK cell...

Introduction CHOP are mostly planned as the first line therapy for PTCL patients. However, in the current modes of treatment strategy, a high incidence of relapse/disease progression/death was observed in PTCL patients. Methods 64 newly diagnosed PTCL patients (25 AITL, 17 PTCL NOS, 11 ALK ALCL and ...

Background: Mogamulizumab is approved to treat relapsed/refractory mycosis fungoides/Sézary syndrome (MF/SS). In the phase 3 MAVORIC study (N=372), mogamulizumab, given 1mg/kg weekly in cycle (C) 1 and then biweekly (Q2W), demonstrated superior efficacy vs vorinostat and a manageable safety profile...

Introduction: Cutaneous T-cell lymphoma (CTCL), including mycosis fungoides (MF) and Sézary syndrome (SS), exhibits survival disparities by race and sex. Objective: This study examined racial and sex-based survival disparities in MF and SS.Methods: Using SEER8 database (1975–2021), we identi...

PURPOSE: Functional precision medicine approaches, including ex vivo drug sensitivity, may improve individualized treatment selection. This is useful for T-cell lymphoma (TCL), which has limited treatment options and is more prevalent in Asian countries. In a previously published clinical feasibilit...

ITK is expressed in T cells and NK cells and is involved in multiple signaling pathways including T cell receptor activation, differentiation of naïve helper T cells and FAS mediated activation-induced cell death. Selective knock-out or inhibition of ITK results in Th1 skewing and enhancement of T ...

Introduction:Human T cell leukaemia virus type 1 (HTLV-1) is the most potent viral driver of cancer in humans, causing adult T cell leukaemia/lymphoma (ATL) in 5% of carriers. We developed a method to detect 'ATL-like' hyper-expanded T cell clones circulating in the blood of HTLV-1 carriers with no ...

Large granular lymphocyte leukemia (LGLL) is a rare type of leukemia that is most prevalent in the elderly population. Standard-of-care treatments include immunosuppressive therapies such as methotrexate, cyclosporine, or cyclophosphamide, but response rates are only modest, and toxicity such as cyt...

Prognostic models in PTCL have identified biological factors as predictors of survival. However, the impact of social determinants of health (SDH) on PTCL outcomes remains unexplored.We conducted a retrospective cohort study to assess the influence of actionable SDH on PTCL mortality across racial g...

Recurrent mutations in enhancers (E) and super-enhancers (SE) contribute to lymphoma tumorigenesis, but their mutational landscape, targets, and functional impact in PTCL remain undefined.Using CUT&RUN (H3K27ac and H3K27me3 marks) and RNA-seq, we mapped the epigenetic landscape of 29 PTCL cell l...

Introduction:Early relapse after stem cell transplantation (SCT) remains common in PTCL. Improved biomarkers may better select patients for SCT in PTCL.  Molecular residual disease (MRD) can inform decisions around SCT, but its utility is limited by confounding clonal hematopoiesis mutations, a...

Introduction: Acquired pure red cell aplasia (PRCA) is a kind of rare bone marrow failure disease characterized by destruction of erythrocyte by the immune system. Patients with PRCA have a response to immunosuppressive therapy, but myelodysplastic syndromes and acute myeloid leukemia develop in som...

DR-01 is a non-fucosylated human IgG antibody targeting CD94, a receptor selectively expressed on cytotoxic terminal effector CD8+T cells, γδT cells, and NK cells, leading to rapid depletion of target cells primarily by antibody-dependent cellular cytotoxicity, including fratricide (cyto...

Introduction:Black patients with cutaneous T-cell lymphoma (CTCL) have increased risk of mortality compared to other racial groups. Methods:We performed a retrospective review of patients seen at Emory to assess racial differences in treatment patterns and their association with outcomes. Thera...

Background: Cutaneous T-cell lymphoma (CTCL) are a heterogeneous group of lymphoproliferative disorders characterized by malignant atypical clonal T lymphocytes with skin involvement, most commonly including mycosis fungoides (MF) and Sezary Syndrome (SS).  MF and SS are difficult to treat...

Introduction:  Folliculotropic mycosis fungoides (FMF) is an aggressive variant of mycosis fungoides (MF). Malignant FMF T-cells localize to the pilosebaceous unit while malignant T-cells in classic MF (CMF) infiltrate the de...

Context:T-cell Lymphoma is a common hematological malignancy in Kosovo compared to the other lymphoid malignancies. These are a variety of subtypes of the disease present. The diagnosis of this disease has increased in the last years and the treatment with chemotherapy and other supportive care has ...

Introduction: T-cell lymphomas (TCL) is a rare and aggressive form of non-Hodgkin's lymphoma characterized by the malignant proliferation of T-cells. Despite recent advances in understanding the disease biology and development of novel therapies, PTCL remains a challenging clinical entity. ...

Introduction: Canine lymphoma (CNL) is similar to the human disease and accounts for ~6% of all cancers in dogs. The majority of CNL are of B-cell origin (B-CNL), although a significant proportion are T-cell lymphoma (T-CNL; ~28%). Standard of care chemotherapy is effective against B-CNL but la...